These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 28125763

  • 1. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial.
    Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A.
    JAMA Oncol; 2017 Jul 01; 3(7):906-912. PubMed ID: 28125763
    [Abstract] [Full Text] [Related]

  • 2. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
    Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.
    JAMA; 2017 Jan 03; 317(1):48-58. PubMed ID: 28030702
    [Abstract] [Full Text] [Related]

  • 3. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
    Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N.
    Lancet Oncol; 2014 Jan 03; 15(1):114-22. PubMed ID: 24332514
    [Abstract] [Full Text] [Related]

  • 4. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
    Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M.
    Int J Clin Oncol; 2010 Aug 03; 15(4):382-9. PubMed ID: 20354750
    [Abstract] [Full Text] [Related]

  • 5. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.
    Breast Cancer Res Treat; 2016 Jan 03; 155(1):77-84. PubMed ID: 26643085
    [Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).
    Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ.
    J Clin Oncol; 2017 Dec 10; 35(35):3949-3955. PubMed ID: 29023215
    [Abstract] [Full Text] [Related]

  • 7. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe T, Goessl C, Ohashi Y, Takashima S.
    J Clin Oncol; 2005 May 20; 23(15):3314-21. PubMed ID: 15738536
    [Abstract] [Full Text] [Related]

  • 8. Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
    McKeage K, Plosker GL.
    Pharmacoeconomics; 2008 May 20; 26(3):251-68. PubMed ID: 18282018
    [Abstract] [Full Text] [Related]

  • 9. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M, Edwards S.
    Support Care Cancer; 2013 Jun 20; 21(6):1557-60. PubMed ID: 23334521
    [Abstract] [Full Text] [Related]

  • 10. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.
    Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM.
    JAMA Intern Med; 2014 Oct 20; 174(10):1550-7. PubMed ID: 25111880
    [Abstract] [Full Text] [Related]

  • 11. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, Rosen L, Kowalski MO, Reitsma D, Seaman J.
    Cancer Invest; 2002 Oct 20; 20 Suppl 2():45-54. PubMed ID: 12442349
    [Abstract] [Full Text] [Related]

  • 12. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
    Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.
    J Manag Care Pharm; 2011 Oct 20; 17(8):621-43. PubMed ID: 21942303
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Oct 20; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 14. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M.
    Curr Med Res Opin; 2007 Jul 20; 23(7):1575-82. PubMed ID: 17559749
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.
    Gordon DH.
    Clin Breast Cancer; 2005 Jun 20; 6(2):125-31. PubMed ID: 16001990
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates and other bone agents for breast cancer.
    O'Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A.
    Cochrane Database Syst Rev; 2017 Oct 30; 10(10):CD003474. PubMed ID: 29082518
    [Abstract] [Full Text] [Related]

  • 17. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ.
    Cancer; 2003 Oct 15; 98(8):1735-44. PubMed ID: 14534891
    [Abstract] [Full Text] [Related]

  • 18. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.
    J Clin Oncol; 2010 Dec 10; 28(35):5132-9. PubMed ID: 21060033
    [Abstract] [Full Text] [Related]

  • 19. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.
    Cancer; 2004 Jun 15; 100(12):2613-21. PubMed ID: 15197804
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.
    Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R, Bogani P, Ripamonti CI.
    Lancet Oncol; 2013 Jun 15; 14(7):663-70. PubMed ID: 23684411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.